Introduction
Gastric cancer (GC) represents the second leading cause of death among all cancer types and caused 782,685 deaths worldwide in 2018. 1 Currently, the incidence of
Data extraction and quality assessment
Data were independently extracted by two investigators (Sun HL, and Bai MH) following the same inclusion criteria; disagreements were adjudicated by the third reviewer (Liu DL). The extracted characteristics were summarized as follows: (I) first author's names, (II) years of publication, (III) study locations, (IV) tumor stages, (V) Karnofsky Performance Score (KPS), (VI) number of cases, (VII) patient ages, (VIII) study parameter types, (IX) therapeutic regimens, (X) enrollment period and (XI) dosage of cinobufotalin. The included trial's quality was evaluated according to the Cochrane Handbook. 43 
Outcome definition
Clinical responses include treatment efficacy, quality of life (QoL) and adverse events. Treatment efficacy was assessed in terms of the overall survival rates (OS rates, defined as the length of time from the start of treatment to death from any cause), complete response (CR) rates, partial response (PR) rates, stable disease (SD) rates, progressive disease (PD) rates, overall response rates (ORRs, ORR=CR + PR) and disease control rates (DCRs, DCR=CR + PR + SD). Patients' QoL was evaluated using QoL improved rate (QIR), KPS and pain relief rate (PRR). Adverse events including nausea and vomiting, diarrhea, leucopenia, thrombocytopenia, hepatotoxicity, nephrotoxicity, oral mucositis, alopecia, hand-foot syndrome, anemia, gastrointestinal adverse effects, peripheral neurotoxicity, neutropenia and myelosuppression were also assessed.
Statistical analysis
RevMan 5.3 (Nordic Cochran Centre, Copenhagen, Denmark) and Stata 13.0 (Stata Corp., College Station, TX, USA) software were the main statistical analysis tools in this study. P<0.05 was considered statistically significant. Analysis model was determined by heterogeneity among studies assessed using Cochran's Q test, and publication bias was analyzed using Begg's and Egger's regression asymmetry tests and presented using funnel plots. 44 I 2 <50% or P>0.1 indicated that the studies were homogenous. Treatment effects were mainly represented by odds ratio (OR) presented with a 95% confidence interval (CI). Pooled analysis with publication bias determined that trim and fill method would be applied to coordinate the estimates of unpublished studies, and the adjusted results were compared with the original pooled OR. 45 Sensitivity analysis was performed to evaluate the impact of different therapeutic regimens, drug forms of cinobufotalin, sample sizes and research types on clinical efficacy.
Results

Search results
A total of 493 articles were identified and initially retrieved, and 275 papers were excluded due to duplication. After title and abstract review, 163 articles were further excluded because they did not include clinical trials (n=127) and were unrelated studies (n=34) or published before 2000 (n=2), leaving 55 studies as potentially relevant. After detailed assessment of full texts, articles without control group (n=8), studies with case reports (n=6), reviews or meta-analysis (n=5), and trials with insufficient data (n=9) were excluded. Finally, 27 trials 16-42 involving 1,939 advanced GC patients were included in this analysis ( Figure 1 ).
Patient characteristics
After selection, all included studies were performed in different medical centers of China since 2000. In total, 972 advanced GC patients were treated with chemotherapy in combination with cinobufotalin adjuvant therapy, while 967 patients were treated with chemotherapy alone. Detailed information of the involved studies and GC patients is shown in Tables 1 and 2 .
Quality assessment
The assessment of bias risk is shown in Figure 2 . A total of 24 studies were determined as having low risk, and the remaining 3 studies were not true randomized controlled trials. All included trials did not provide clear description of performance and detection risks. The attrition risks of involved trials were low; 9 trials were considered as having unclear risk owing to selective reporting.
Therapeutic efficacy assessment
As shown in Figures 3 and 4 , Figure S1 and 
Adverse event assessment
As shown in Table 4 and Figure S2, 
Publication bias
Funnel plots drawn for the studies on primary outcomes (CR, PR, SD, PD, ORR, DCR and adverse events) were approximately symmetrical, which indicated generally controlled publication bias and reliability of our primary conclusions ( Figure 6 and S3). We also assessed publication bias using Begg's and Egger's regression asymmetry tests (Table 5) , and PR and leucopenia were found with bias (PR, Begg, 0.038; Egger, 0.015; leucopenia, Begg, 0.003; Egger, <0.0001). To determine if the bias affects the pooled risk, we conducted a trim and fill analysis. The adjusted OR rate indicated the same trend with the result of the primary analysis (PR [before, P<0.0001; after, P<0.0001], leukopenia [before, P=0.0002; after. P=0.0002]), reflecting the 
Sensitivity analysis
We performed subgroup analysis to explore the source of heterogeneity in ORR and DCR with respect to therapeutic regimens, drug forms of cinobufotalin, sample sizes and research types. As shown in Table 6 , our analysis results showed that no significant difference was found between different forms of cinobufotalin, sample sizes and research types. Moreover, cinobufotalin combined with FOLFOX/ XELOX/capecitabine chemotherapy regimens was found to be more effective for GC treatment.
Discussion
In view of the limitations of the current chemotherapy for malignancies such as drug resistance and toxic side effects, clinicians have been exploring complementary and alternative medicine treatments to improve patients' survival time or QoL and reduce side effects caused by chemotherapy. 6, 10, 46, 47 Traditional Chinese medicine, particularly cinobufotalin, has been clinically applied as an adjuvant therapy for decades. 7, 10, 11 Several studies have been reported that the addition of cinobufotalin could be beneficial to advanced GC patients. Even though there was a statistical analysis of published clinical trials, the exact therapeutic effects were still not systematically evaluated because of small sample sizes and different applied protocols in different studies. Therefore, in this analysis, we conducted a wide range of online search according to strict inclusion and exclusion criteria to provide clear and systematical conclusion. Our meta-analysis revealed that cinobufotalin and chemotherapy combined therapy for GC patients achieved Figure 5 Forest plot of the comparison of quality of life improved rate (QIR, A), karnofsky performance score (KPS, B) and pain relief rate (PRR, C) between the experimental and control group. Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. The fixed-effects metaanalysis model (Mantel-Haenszel method) was used. more beneficial effects in comparison with those treated with chemotherapy alone. Combined therapy-treated patients broadly exhibited increased ORR and DCR (P<0.05) and also significantly improved their QoL. These results indicated that using cinobufotalin could improve the curative effects of chemotherapy. Safety is the top priority of the clinical treatment. One trial 7 that was conducted at Fudan University Cancer
Hospital showed that cinobufotalin is well tolerated by hepatocellular carcinoma, non-small-cell lung cancer and pancreatic cancer patients (only mild adverse events were observed in cancer patients who received cinobufotalin therapy; no grade III and IV toxicities were observed). Our analysis showed that most of the adverse events caused by chemotherapy, including nausea and vomiting, diarrhea, leucopenia, hand-foot syndrome, anemia, gastrointestinal side effects and peripheral neurotoxicity, were alleviated with cinobufotalin combination therapy (P<0.05). Therefore, cinobufotalin is a safe auxiliary antitumor medicine for GC and can effectively alleviate the adverse events associated with chemotherapy. The analysis on therapeutic effects may be influenced by several factors. In our study, no difference was found between different drug forms of cinobufotalin, sample sizes and research types. Cinobufotalin combined with FOLFOX/ XELOX/capecitabine chemotherapy regimens was more effective for GC treatment (Table 6 ). However, a comparative analysis of the above-mentioned individual chemotherapy regimens should be performed in the future to rule out the possibility that the therapeutic advantage of cinobufotalin combined with FOLFOX, XELOX or capecitabine is due to the better therapeutic effect of them alone compared to that of EOF. As a summary, recent studies on the impact of these factors on the curative effects of cinobufotalin adjuvant therapy remain insufficient, and hence, further investigations should be performed.
There are some limitations in our analysis. First, although traditional Chinese medicine has been exported to 185 countries and regions, its main markets still remained in Asia. 48 As a traditional medicine, cinobufotalin was mainly applied in China, which may bring the unavoidable regional bias and subsequently influence the clinical application of cinobufotalin worldwide. Second, according to the Cochrane Handbook for systematic reviews of interventions, the most appropriate way of summarizing survival outcomes is to use methods of survival analysis and express the intervention effect as a hazard ratio (HR) because this method takes into consideration the time factor and censored participants. However, the included articles that reported the OS rate only provided the survival number and the total number of patients at 6 months and 12 months, and none of them provided HR with 95% CI and Kaplan-Meier survival curves. Therefore, there were insufficient data to perform a statistical analysis using HR, which almost certainly will introduce bias. Third, treatment/medical history is very important in evaluating the efficacy of cinobufotalinmediated therapy. However, our data were partly extracted from published papers rather than from the original patient records; therefore, analytical bias would possibly exist. Moreover, the therapeutic effects of the combined therapy may be influenced by numerous variables such as dosage of cinobufotalin, tumor stage and patient's age. However, based on currently available literature, there are insufficient data to perform more statistical analysis to evaluate the correlation. We will keep following up with upcoming clinical trials to obtain relevant data when available. Finally, the follow-up durations of the included studies were short, and the long-term efficacy of cinobufotalin for advanced GC remains to be further evaluated.
Conclusion
In summary, this meta-analysis indicated that cinobufotalin and chemotherapy combined therapy was effective in treating advanced GC. Clinical application of cinobufotalin not only evidently improved the therapeutic effects of chemotherapy but also effectively alleviated most of the side effects caused by chemotherapy. However, the longterm efficacy of cinobufotalin-mediated adjuvant therapy for advanced GC still needs methodologically rigorous trials to verify its efficacy. 
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Supplementary materials Figure S1 Forest plot of the comparison of complete response rates (CR, A), partial response rates (PR, B), stable disease rates (SD, C) and progressive disease rates (PD, D) between the experimental and control group. Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. The fixed-effects meta-analysis model (Mantel-Haenszel method) was used. OncoTargets and Therapy
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